Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks with Bloomberg's Dani Burger. 

Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly&rsquo;s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks with Bloomberg's Dani Burger.&nbsp;

Listen for top interviews from Bloomberg News. 

Hear conversations with the biggest names in finance, politics, technology, foreign relations, sports and entertainment.

Listen for top interviews from Bloomberg News. Hear conversations with the biggest names in finance, politics, technology, foreign relations, sports and entertainment.

Listen to top interviews from Bloomberg News.

Bloomberg Talks

Novo's Martin Holst Lange Talks New Weight Loss Shot

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/55950a5c-8908-4f1c-a819-b3fa01192054/transcript